Loading stock…

Takeda Pharmaceutical Company Limited (TAK) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

Takeda Pharmaceutical Company Limited

TAKMarket cap $58BPrice $18.4

Country🇯🇵Japan

SectorHealthcare

IndustryPharmaceuticals

Develops and manufactures prescription drugs with a focus on rare diseases and cancer treatments. This Japanese pharma giant owns one of the world's largest collections of plasma-derived therapies for ultra-rare conditions.

In Bastion Portfolios?

52W Return+31%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)-2%2

Revenue Forecast

Rev CAGR (1y)+4%4

Rev CAGR (3y)+3%2

Rev CAGR (5y)+3%3

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+2Loss1

EPS Growth Y+3Loss1

Quality

Margins

EBIT Margin14%6

Net Income Margin-4%2

Free Cash Flow Margin17%7

Debt

Net Debt/EBITDA3.92

Efficiency

ROE-2%2

ROA-1%2

Earnings Stability22

GEAR+VERY WEAK15

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)352

P/E Ratio (Forward 3y)na–

P/BV1.29

EV Multiples

EV/EBITDA Fwd125

EV/EBIT Fwd312

Yield

Free Cash Flow Yield8.3%8

Dividend Yield2.6%6

Momentum

Short term

1 month return+0%8

3 month return+10%8

YTD return+19%7

Mid term

Price vs 52wHigh96%10

1 year return+30%8

Long term

3 year return+32%4

5 year return+51%6

Risk Shield

Price Risk

Beta0.48

Volatility21%9

Free Cash Flow

Free Cash Flow Margin17%7

Free Cash Flow Yield8.3%8

Quality

ROCE5%3

Earnings Stability22

Net Debt/EBITDA3.92

02Growth

Is it actually growing, and how fast?

TAKTakeda Pharmaceutical Company

Revenue FY26$28.4B

GROWTH RATING↗

VERY WEAK8 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-2%2

Revenue, next 1Y+4%4

Revenue, next 3Y, CAGR+3%2

Revenue, next 5Y, CAGR+3%3

EARNINGS FORECAST▾SCORE

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

EPS growth, FY29ELoss1

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

After shrinking over the last 3 years, revenue is set to grow 3%/yr from here.

WEAKNESSES

Growth is the weak spot here, trailing 92% of companies worldwide.

Revenue fell 2%/yr over the last 3 years, behind 80% of companies worldwide.2/10

Revenue is set to grow 3%/yr over the next 3 years, behind most of the market.3/10

Over five years revenue is set to grow 3%/yr, behind 70% of companies worldwide.3/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business that's turning around. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG81 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+0%8

3-month return+10%8

YTD return+19%7

MID & LONG-TERM▾SCORE

% of 52-week high96%10

1-year return+30%8

3-year return+32%4

5-year return+51%6

MOMENTUM ASSESSMENT

STRENGTHS

It's up 30% over the past year, now sitting right at its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+0%), over three months (+10%) and so far this year (+19%).

WATCH

Average long-term results. Multi-year returns are middling (+32% over three years and +51% over five), roughly average for the market.

WEAKNESSES

None flagged.

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case.

04Value

Are you paying a fair price for it?

Stop guessing on Takeda. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

TAKTakeda Pharmaceutical Company

Revenue FY26$28.4B

GROWTH RATING↗

VERY WEAK8 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-2%2

Revenue, next 1Y+4%4

Revenue, next 3Y, CAGR+3%2

Revenue, next 5Y, CAGR+3%3

EARNINGS FORECAST▾SCORE

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

EPS growth, FY29ELoss1

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

After shrinking over the last 3 years, revenue is set to grow 3%/yr from here.

WEAKNESSES

Growth is the weak spot here, trailing 92% of companies worldwide.

Revenue fell 2%/yr over the last 3 years, behind 80% of companies worldwide.2/10

Revenue is set to grow 3%/yr over the next 3 years, behind most of the market.3/10

Over five years revenue is set to grow 3%/yr, behind 70% of companies worldwide.3/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business that's turning around. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG81 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+0%8

3-month return+10%8

YTD return+19%7

MID & LONG-TERM▾SCORE

% of 52-week high96%10

1-year return+30%8

3-year return+32%4

5-year return+51%6

MOMENTUM ASSESSMENT

STRENGTHS

It's up 30% over the past year, now sitting right at its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+0%), over three months (+10%) and so far this year (+19%).

WATCH

Average long-term results. Multi-year returns are middling (+32% over three years and +51% over five), roughly average for the market.

WEAKNESSES

None flagged.

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case.

04Value

Are you paying a fair price for it?

Stop guessing on Takeda. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community